Johnson & Johnson (JNJ): This leading healthcare company holds a PSR of 2.7, not much higher than its 10-year low of 2.14, and sports a P/E ratio of 12.6. While recent product recalls could hurt the JNJ brand and cost millions of dollars, the firm is too diverse, too financially healthy, and too well run to not overcome the setback. And considering that the firm holds the #1 or #2 spot in 70% of its products, a product recall would have to cause major damage to the brand in order to significantly affect such strong control of the market.
Shares trade for around $60, below our fair value of $81 for 2011. Shares also yield 3.6% at the current price. Due to the high yield and high business predictability predictability, JNJ also makes a great retirement buy, as we wrote here.
If you read the piece it is well managed as well. So it's either a personal thing or you don't know what you are talking about. I don't see Warren Buffet complaining or Vanguard. So who are you to complain with a few shares that don't matter. Get off the Bill Weldon thing and grow up.